Accessibility Menu
Vertex Pharmaceuticals logo

Vertex Pharmaceuticals

(NASDAQ) VRTX

Current Price$468.89
Market Cap$118.47B
Since IPO (1991)+10,273%
5 Year+144%
1 Year+6%
1 Month+8%

Vertex Pharmaceuticals Financials at a Glance

Market Cap

$118.47B

Revenue (TTM)

$12.26B

Net Income (TTM)

$4.34B

EPS (TTM)

$16.87

P/E Ratio

27.67

Dividend

$0.00

Beta (Volatility)

0.58 (Low)

Price

$468.89

Volume

1,204,019

Open

$469.67

Previous Close

$468.42

Daily Range

$463.76 - $470.82

52-Week Range

$362.50 - $507.92

Estimated Earnings Date

Aug 3, 2026

VRTX: Motley Fool Moneyball Superscore

87

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Vertex Pharmaceuticals

Industry

Biotechnology

Employees

6,400

CEO

Reshma Kewalramani, MD

Headquarters

Boston, MA 02210, US

VRTX Financials

Key Financial Metrics (TTM)

Gross Margin

86.28%

Operating Margin

38.97%

Net Income Margin

35.40%

Return on Equity

23.93%

Return on Capital

21.11%

Return on Assets

16.38%

Earnings Yield

3.61%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$118.47B

Shares Outstanding

253.81M

Volume

1.20M

Avg. Volume

1.28M

Financials (TTM)

Gross Profit

$10.57B

Operating Income

$4.78B

EBITDA

$5.39B

Operating Cash Flow

$4.24B

Capital Expenditure

-$530.30M

Free Cash Flow

$3.71B

Cash & ST Invst.

$7.25B

Total Debt

$1.99B

Vertex Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$2.99B

+7.8%

Gross Profit

$2.59B

+7.8%

Gross Margin

86.85%

N/A

Market Cap

$118.47B

N/A

Market Cap/Employee

$19.42M

N/A

Employees

6,100

N/A

Net Income

$1.03B

+59.6%

EBITDA

$1.31B

+67.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$7.25B

+16.9%

Total Debt

$1.99B

+20.5%

Accounts Receivable

$2.00B

+10.6%

Inventory

$1.77B

+29.9%

Long Term Debt

$1.99B

+20.5%

Short Term Debt

$0.00

N/A

Return on Assets

16.38%

N/A

Return on Invested Capital

21.13%

N/A

Free Cash Flow

$1.29B

+66.4%

Operating Cash Flow

$1.43B

+74.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SYKStryker Corporation
$310.00+1.74%
BMYBristol-Myers Squibb Company
$55.53+1.52%
CVSCVS Health Corp.
$101.57+0.27%
GSKGSK plc
$52.07+2.62%

Trending Stocks

Symbol / CompanyPricePrice Chg
AALAmerican Airlines Group
$16.14+0.00%
NOKNokia
$13.70-0.05%
TQQQProShares Trust - ProShares UltraPro Qqq
$74.44-0.10%
PFEPfizer
$24.72-0.01%

Questions About VRTX

What is the current price of Vertex Pharmaceuticals?

Vertex Pharmaceuticals is trading at $468.42 per share.

What is the 52-week range for Vertex Pharmaceuticals?

Over the past 52 weeks, Vertex Pharmaceuticals has traded between $362.50 and $507.92.

How much debt does Vertex Pharmaceuticals have?

As of the most recent reporting period, Vertex Pharmaceuticals reported total debt of $1.99B.

How much cash does Vertex Pharmaceuticals have on hand?

Vertex Pharmaceuticals reported $5.50B in cash and cash equivalents in its most recent financial results.

What is Vertex Pharmaceuticals’s dividend yield?

Vertex Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.